Your browser doesn't support javascript.
loading
Timing of bioprosthetic valve fracture in transcatheter valve-in-valve intervention: impact on valve durability and leaflet integrity.
Meier, David; Payne, Geoffrey W; Mostaço-Guidolin, Leila B; Bouchareb, Rihab; Rich, Courtney; Lai, Althea; Chatfield, Andrew G; Akodad, Mariama; Salcudean, Hannah; Lutter, Georg; Puehler, Thomas; Pibarot, Philippe; Allen, Keith B; Chhatriwalla, Adnan K; Sondergaard, Lars; Wood, David A; Webb, John G; Leipsic, Jonathon A; Sathananthan, Janarthanan; Sellers, Stephanie L.
Afiliação
  • Meier D; Centre for Cardiovascular Innovation, St Paul's and Vancouver General Hospital, Vancouver, BC, Canada.
  • Payne GW; Cardiovascular Translational Laboratory, Providence Research & Centre for Heart Lung Innovation, Vancouver, BC, Canada.
  • Mostaço-Guidolin LB; Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
  • Bouchareb R; University of Northern British Columbia, Prince George, BC, Canada.
  • Rich C; Department of Systems and Computer Engineering, Carleton University, Ottawa, ON, Canada.
  • Lai A; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Chatfield AG; ViVitro Labs Inc., Victoria, BC, Canada.
  • Akodad M; Cardiovascular Translational Laboratory, Providence Research & Centre for Heart Lung Innovation, Vancouver, BC, Canada.
  • Salcudean H; Centre for Cardiovascular Innovation, St Paul's and Vancouver General Hospital, Vancouver, BC, Canada.
  • Lutter G; Cardiovascular Translational Laboratory, Providence Research & Centre for Heart Lung Innovation, Vancouver, BC, Canada.
  • Puehler T; Centre for Cardiovascular Innovation, St Paul's and Vancouver General Hospital, Vancouver, BC, Canada.
  • Pibarot P; Cardiovascular Translational Laboratory, Providence Research & Centre for Heart Lung Innovation, Vancouver, BC, Canada.
  • Allen KB; Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
  • Chhatriwalla AK; Cardiovascular Translational Laboratory, Providence Research & Centre for Heart Lung Innovation, Vancouver, BC, Canada.
  • Sondergaard L; Department of Cardiac and Vascular Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Wood DA; DZHK (German Centre for Cardiovascular Research), partner site Kiel/Hamburg, Hamburg, Germany.
  • Webb JG; Department of Cardiac and Vascular Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Leipsic JA; DZHK (German Centre for Cardiovascular Research), partner site Kiel/Hamburg, Hamburg, Germany.
  • Sathananthan J; Québec Heart and Lung Institute, Department of Medicine, Laval University, Québec, QC, Canada.
  • Sellers SL; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, USA.
EuroIntervention ; 18(14): 1165-1177, 2023 Feb 20.
Article em En | MEDLINE | ID: mdl-36534495
ABSTRACT

BACKGROUND:

Bioprosthetic valve fracture (BVF) can be used to improve transcatheter heart valve (THV) haemodynamics following a valve-in-valve (ViV) intervention. However, whether BVF should be performed before or after THV deployment and the implications on durability are unknown. 

Aims:

We sought to assess the impact of BVF timing on long-term THV durability.

METHODS:

The impact of BVF timing was assessed using small ACURATE neo (ACn) or 23 mm SAPIEN 3 (S3) THV deployed in 21 mm Mitroflow valves compared to no-BVF controls. Valves underwent accelerated wear testing up to 200 million (M) cycles (equivalent to 5 years). At 200M cycles, THV were evaluated by hydrodynamic testing, second-harmonic generation (SHG) microscopy, scanning electron microscopy (SEM) and histology.

RESULTS:

At 200M cycles, the regurgitant fraction (RF) and effective orifice area (EOA) for the ACn were 8.03±0.30%/1.74±0.01 cm2 (no BVF), 12.48±0.70%/1.97±0.02 cm2 (BVF before ViV) and 9.29±0.38%/2.21±0.0 cm2 (BVF after ViV), respectively. For the S3 these values were 2.63±0.51%/1.26±0.01 cm2, 2.03±0.42%/1.65±0.01 cm2, and 1.62±0.38%/2.22±0.01 cm2, respectively. Further, SHG and SEM revealed a higher degree of superficial leaflet damage when BVF was performed after ViV for the ACn and S3. However, the histological analysis revealed significantly less damage, as determined by matrix density analysis, through the entire leaflet thickness when BVF was performed after ViV with the S3 and a similar but non-significant trend with the ACn. 

Conclusions:

BVF performed after ViV appears to offer superior long-term EOA without increased RF. Ultrastructure leaflet analysis reveals that the timing of BVF can differentially impact leaflets, with more superficial damage but greater preservation of overall leaflet structure when BVF is performed after ViV.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Bioprótese / Próteses Valvulares Cardíacas / Substituição da Valva Aórtica Transcateter Limite: Humans Idioma: En Revista: EuroIntervention Assunto da revista: ANGIOLOGIA / CARDIOLOGIA / TERAPEUTICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Bioprótese / Próteses Valvulares Cardíacas / Substituição da Valva Aórtica Transcateter Limite: Humans Idioma: En Revista: EuroIntervention Assunto da revista: ANGIOLOGIA / CARDIOLOGIA / TERAPEUTICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá